Issues. Non-injectable naloxone formulations are being developed for opioid overdose reversal, but only limited data have been published in the peer-reviewed domain. Through examination of a hitherto-unsearched database, we expand public knowledge of non-injectable formulations, tracing their development and novelty, with the aim to describe and compare their pharmacokinetic properties. Approach. (i) The PatentScope database of the World Intellectual Property Organization was searched for relevant English-language patent applications; (ii) Pharmacokinetic data were extracted, collated and analysed; (iii) PubMed was searched using Boolean search query '(nasal OR intranasal OR nose OR buccal OR sublingual) AND naloxone AND pharmacokinetics'. Key Findings. Five hundred and twenty-two PatentScope and 56 PubMed records were identified: three published international patent applications and five peer-reviewed papers were eligible. Pharmacokinetic data were available for intranasal, sublingual, and reference routes. Highly concentrated formulations (10-40 mg mL
Introduction
On 18 November 2015, the US Food and Drug Administration (FDA) gave regulatory approval for a concentrated intranasal (IN) naloxone spray by Adapt Pharma [1] , which constitutes the first-ever licensed non-injectable naloxone product. Regulatory approval in Canada followed in October 2016 [2] . The FDA and Health Canada decisions have opened up the possibility, for North America at least, of wider access to naloxone in light of the rising death toll from opioid overdoses [3] . At an estimated 106 000 deaths per annum [4] , opioid overdose deaths are also a growing international public health concern. To date, globally, no other non-injectable naloxone formulation has been licensed.
Effective non-injectable naloxone products would remove the risk of needle-stick injury in medical and community settings. Non-injectable naloxone may offer a particular implementation advantage for take-home naloxone (THN) programs, that is, the pre-placement of naloxone kits with opioid users, families, peers, community police and staff at treatment services, dropin centres and hostels, where it would likely reduce regulatory obstacles and the current requirement of training laypersons in needle-and-syringe assembly and administration [5] . First proposed in 1996 [6] , THN has increasingly been introduced in the past decade, and recent World Health Organization (WHO) guidelines and a UN declaration have called for naloxone access for 'anyone likely to witness an overdose' [7, 8] . In response, the FDA, the US Centers for Disease Control and Prevention, National Institute on Drug Abuse and Office of the Assistant Secretary for Health and Human Services sponsored a 2012 stakeholder meeting where key criteria for any novel non-injectable naloxone product were proposed [9, 10] .
According to the FDA [9] , one or more standardised doses of a novel non-injectable naloxone formulation would need to result in plasma naloxone levels (i.e. area under the curve; AUC) comparable with a parenteral dose of at least 0.4 mg. If the bioavailability [(F = 'absolute bioavailability', relative to intravenous; F IM = 'relative bioavailability', relative to intramuscular (IM)] of the new product compared with the approved injection is low, then it is unclear if adequate efficacy can be reached. Vice versa, if the bioavailability is unexpectedly high, then this may have implications for the safety profile of the novel formulation. Furthermore, the bioavailability compared with injection would need to be reasonably constant between different individuals. In the emergency situation of opioid overdose, naloxone needs to be absorbed rapidly. Absorption would thus need to be at least as rapid as IM injection, whereby onset of effect starts within 3 to 7 min of administration [8] . The key pharmacokinetic (PK) parameters for a non-injectable naloxone formulation are typically the maximum observed plasma concentration (C max ) and the time from dosing to peak concentration (T max ), in addition to bioavailability.
A recent systematic review [11] applied the FDA criteria to the peer-reviewed literature and identified three candidate routes of administration for injectionfree naloxone delivery: IN, sublingual and buccal. However, at the time of the FDA approval of the first nasal spray, no results from clinical trials on the new nasal spray were published, and human PK data were only reported in one peer-reviewed publication for an improvised IN naloxone spray formulation (2 mg 5 mL À1 ), with extremely low bioavailability (F = 4%) [12] . While improvised IN spray devices (administered by attaching a mucosal atomiser device to a pre-filled 2 mg 2 mL À1 naloxone syringe) are commonly used in THN programs in some countries and a significant number of overdose reversals have been reported [13, 14] , uncertainties regarding their efficacy have been considered and primarily concern their potential non-response rate and lack of safety data [15] [16] [17] .
Time lag between research and development activity in the pharmaceutical industry and the publication of relevant data in the peer-reviewed literature is not new: Indeed, more than five decades ago, the discovery and original synthesis of naloxone was first reported in a 1961 patent application [18] before a conference abstract [19] and a full journal article [20] followed in subsequent years.
This exploratory review attempts to close the existing gap in the literature by examining published international patent applications of non-injectable naloxone formulations and contributory PK data. The aims are threefold: (i) to trace the concept and product development by route of administration; (ii) to describe the non-injectable naloxone formulations for which human in vivo data are available; and (iii) to compare human PK data reported in the patent applications.
Methods
A three-stage approach has been taken.
Stage 1
The PatentScope database of the World Intellectual Property Organization (WIPO), which contains 58 million patent documents including 3 million published international patent applications [21] , was searched for patent applications for non-injectable naloxone formulations. PatentScope was searched for Englishlanguage patent applications ('Language: EN') that were registered with any international patent office ('Office(s): all') and contained the search term 'naloxone' within their First Page (default). Only patent applications for non-injectable naloxone that contained human PK data were eligible for inclusion in the analysis [Aims (ii) and (iii)].
Stage 2
The pharmaceutical properties of the non-injectable naloxone formulations and human PK data were extracted from patent applications and summarised. To improve comparability between formulations, doseadjusted values per 1 mg were generated.
Stage 3
To supplement and cross-check the data obtained in Stages 1 and 2, we also searched PubMed for human PK data for non-injectable naloxone using the Boolean search query '(nasal OR intranasal OR nose OR buccal OR sublingual) AND naloxone AND pharmacokinetics' (see Table S1 for search protocol). These three routes of administration were chosen based on the systematic review [11] .
For all three stages, R.M. and Ø.D.G. conducted the PatentScope and PubMed searches, assessed retrieved records for eligibility and extracted relevant information under supervision of the senior authors (O.D. and J.S.).
Results

Stage 1
A PRISMA flow diagram of the selection process of patent applications is shown in Figure 1 . Five hundred and twenty-two PatentScope records were identified using the search term 'naloxone' for front-page matches. At this stage, a cross-check was made for known patent applications, and it was found that no entry for the FDA-approved Adapt IN spray product had been captured. We thus additionally searched PatentScope for 'Adapt OR Lightlake'-related entries. In late 2014, Adapt Pharma had bought the global license from Lightlake Therapeutics Inc. to develop and commercialise their IN naloxone spray [22] . After matching for the search term 'Lightlake' (front-page search, English language, all patent offices), this additional search yielded five patent applications, which had not been captured using the search term 'naloxone' because Lightlake had not included the word 'naloxone' on the front page. Consequently, we manually added these five Lightlake patent applications (n.b. in the following, we denote these as 'Lightlake' unless we refer directly to the licensed Adapt nasal spray product).
Of the 47 records that remained after removing 480 irrelevant records, 10 were excluded based on their abstract (e.g. active ingredient other than naloxone). The remaining 37 records were downloaded for full-text review and screened for human PK data. Of the 14 patent applications that contained relevant PK data, 11 were excluded for the following reasons: five reported only animal data, and six were duplicates (earlier or later versions of patents containing the same PK data but A timeline of the publication of all 37 patent applications (including excluded records) is provided in Table S2 of the Online Appendix. The timeline shows that the concept of non-injectable naloxone (drops, spray, solution, suspension, ointment or gel) was first being explored at the University of Kentucky, with first animal data reported in 1982. The 1990s showed no activity for IN naloxone except for the patent application ) and Lightlake (10, 20 and 40 mg mL
À1
) are described in detail in Table S4 of the Online Appendix; Euro-Celtique only reported the concentration of their formulations (20 mg mL À1 , 40 mg mL À1 Naloxone HCl). All PK data were obtained using cross-over study designs, although sample sizes differed from 7 to 35 subjects per arm. For a full summary of the PK data (including reference routes), please see Table 1 .
AntiOp described two studies, which are hereby referred to as 'Trial 1 (Pilot)' and 'Trial 2'. AntiOp tested a 10 mg mL À1 IN formulation administered as 0.1 mL into one and two nostrils, as well as 0.2 mL per nostril (0.1 + 0.1 mL with 5 min interval). Trial 1 (Pilot) also tested non-concentrate 1 mg mL À1 naloxone, with mucosal atomiser device attached to a syringe, thus replicating the improvised IN naloxone distributed off-label in several countries.
Lightlake presented results from two studies: Study 1 assessed a 10 mg mL À1 formulation, whereas Study 2 tested 20 and 40 mg mL À1 formulations, all administered as 0.1 mL into one and two nostrils (total volume: 0.2 mL).
Euro-Celtique tested IN doses of 8 mg (0.2 mL per nostril; 20 mg mL À1 concentration) and 16 mg (0.2 mL per nostril; 40 mg mL À1 concentration). Euro-Celtique also included a sublingual arm (16 mg mL À1 solution), but this route is not described here in detail, as its absolute bioavailability was only 1%.
For IN administration, we present F as well as F IM , as neither measure was reported across all three patent applications. (Euro-Celtique only provided F, whereas the more recent AntiOp and Lightlake patent applications reported F IM in accordance with guidance from the FDA).
F: For the Euro-Celtique data, we calculated F values of 22% (20 mg mL
, administered as 0.2 mL per nostril) and 21% (40 mg mL
; 0.2 mL per nostril) using AUC 0-∞ data listed in the PK data appendix of the patent application. We were unable to obtain the higher F values of 32% (20 mg mL À1 formulation) and 27% (40 mg mL À1 ), which Euro-Celtique cited in-text for lower doses (1.2 and 1.6 mg, dose-adjusted from 8 and 16 mg) in the body of the patent application. AntiOp only reported F IM , but included an IV reference in Trial 1 (Pilot), which allowed us to determine the following F-values for comparison: 36% (0.1 mL, one nostril only) and 42% (0.1 mL per nostril) for the 10 mg mL À1 formulation, and 11% for non-concentrate naloxone (1 mg mL À1 per nostril). F IM : Lightlake achieved the highest F IM values across all three patent applications, with 0.1 mL of the 10 mg mL À1 formulation administered into both nostrils (F IM = 57%). F IM was lower (48%), when the volume of the same formulation was doubled (0.2 mL per nostril). For the 20 mg mL À1 formulation, F IM was 54% (0.1 mL, one nostril only) and 55% (0.1 mL per nostril). The 40 mg mL À1 formulations achieved 49% and 45% when administered into one and both nostrils, respectively. AntiOp reported the following F IM values for a 10 mg mL À1 formulation: 34% (0.1 mL, one nostril only), 31-39% (0.1 mL per nostril) and 26% (0.1 mL per nostril, with re-administration after 5 min; i.e. total volume of 0.2 mL per nostril). Non-concentrate naloxone (1 mg mL À1 per nostril) had an F IM of 10%. t 1/2 : The terminal half-life (t 1/2 ) is the time it takes for the blood concentration of a pharmacological agent to decrease by 50%, which usually translates into the loss of half of its pharmacological activity. Euro-Celtique reported the longest terminal half-lives (t 1/2 ) for IN Additional exploratory analyses: In order to examine the potential influence of spray concentration on IN absorption, we plotted AUC, C max, and t max values against volume (adjusted by dose for AUC and C max ) and dose ( Figure 2 ). For both AUC and C max , the plots indicate a positive association with dose and a negative association with volume of the IN spray. The graphs do not suggest a clear association for t max .
Stage 3
The PubMed search generated 56 matches, with zero duplicates (see Figure 3 for PRISMA diagram). Fortysix papers were excluded based on title and abstract (no primary research data from human-subject naloxone studies). The 10 remaining records were then downloaded for full text, with five papers excluded for the following reasons: one was a review article, and four did not include naloxone PK data (see Table S3 for list of excluded studies). The remaining eligible five papers included human PK data in two papers for IN naloxone [12, 24] and three papers for sublingual naloxone [25] [26] [27] . None of the papers contained human PK data for buccal naloxone.
Divergent bioavailability values have been reported for IN naloxone. One healthy volunteers study (n = 6) assessed a non-concentrate formulation of IN naloxone (2 mg 5 mL
À1
) and reported an absolute bioavailability of only 4%, which the authors attributed as possibly because of the dilute solution (and high volume) used [12] . Higher absorption was reported in a study [24] with recreational prescription opioid users (n = 10) where absolute bioavailability of IN administration of crushed buprenorphine/naloxone (4:1 ratio) of two concentrations (0.5 and 2 mg naloxone) was 24% and 30%, respectively. Systemic uptake after sublingual naloxone administration was generally found to be low. In one healthy volunteers study, naloxone doses of 1.4 and 2 mg were administered in combination with buprenorphine, resulting in a median t max of 0.8 h and peak naloxone plasma concentrations below 0.4 ng mL À1 for both doses [26] . A second study in non-dependent opioid users (n = 8) [27] assessed escalating naloxone doses (1, 2 and 4 mg) and found that dose-effect comparisons were impossible, as many naloxone plasma concentrations were below the level of quantification (0.050 ng mL
). The highest individual AUC reported was 0.55 ng * h mL
. A third study [25] suggested that sublingual naloxone bioavailability is negatively associated with healthy liver functioning. A sublingual 0.5 mg naloxone tablet (in combination with 2 mg buprenorphine) was administered to 43 subjects stratified by hepatic impairment (mild, moderate or severe), HCV diagnosis without hepatic impairment, and healthy volunteers. Across all groups, the median t max ranged from 0.8 to 1.1 h, with mean t 1/2 from 1.9 to 5.5 h. However, the AUC 0-last data revealed an approximate 3 to 14-fold increase in total naloxone exposure in subjects with moderate and severe hepatic impairment. Likewise, the naloxone C max was 3 to 11 times higher in subjects with hepatic impairment.
Discussion
Human PK data for purpose-made non-injectable naloxone formulations had not been reported in peerreviewed scientific papers at the time of the FDAapproval of the first IN naloxone spray [28] . However, published international patent applications by the companies AntiOp, Euro-Celtique and Lightlake contain data on concentrated sublingual and IN spray formulations in the range 10-40 mg mL
À1
. Through integration of data from WIPO PatentScope and scientific publications retrieved via PubMed, this exploratory review charts R&D activity over the past two decades (particularly 2012-present) and provides an assessment of the current status of non-injectable naloxone development relative to pre-defined regulatory criteria [9, 10] .
Statement of principal findings
Across all concentrate IN naloxone formulations, bioavailability was 21-42% relative to IV and 26-57% relative to IM. We plotted AUC 0-∞ and C max values and found a moderately linear relationship with dose (higher dose ➔ higher AUC 0-∞ , C max ) and a negative association for volume (lower volume ➔ higher AUC 0-∞ , C max ). The highest IN bioavailability (F IM = 57%) was reached when 0.1 mL of a 10 mg mL À1 formulation was administered into both nostrils. For the same formulation, F IM decreased to 48% when volume doubled to 0.2 mL per nostril. Volume clearly matters. Also, dose-concentration linearity is evident. We identify the importance of (low) volume with IN bioavailability drastically lower (F = 11%) when a non-concentrate formulation of 
mg mL
À1 was administered into both nostrils. This confirms previous reports of low bioavailability (F = 4%) for dilute IN spray (0.4 mg mL À1 ) [12] . Sublingual naloxone administration of a concentrate solution (16 mg mL À1 ) had very low bioavailability (F = 1%). This is below the range of 7-9% identified by Chiang et al. in their review of sublingual buprenorphine-naloxone formulations [29] . We conclude that sublingual is unlikely to be a route of administration of clinical value.
Strengths and weaknesses of the review
This is the first review of non-injectable concentrate naloxone formulations in the peer-reviewed literature. It includes examination of public-domain information from patent applications. A core strength of this exploratory review lies in the integration of empirical evidence from PubMed and WIPO PatentScope databases, capturing both academic and pharmaceutical industry advances in the field.
The validity of our comparison of IN PK data across different patent applications is strengthened by the similarity of the IN spray formulations used. While Euro-Celtique only disclosed dose concentrations, all formulations all formulations by Lightlake and AntiOp with provided PK data are characterised by absence of absorption enhancers (which increase membrane permeation) and viscosity-increasing agents (which increase the residence time of naloxone to the nasal mucosa and thus contributes to better absorption) (see Table S4 in Online Appendix).
Potential limitations need to be considered. Firstly, not all research and development activity leads to registration of intellectual property or to journal publication, and non-significant or negative results have low likelihood of getting published. Secondly, data in patent applications are not peer-reviewed.
Thirdly, our exploratory WIPO PatentScope database search was unlikely exhaustive. Considering that our search initially failed to capture the Lightlake patent applications, we cannot rule out the possibility of other false-negatives. We conducted the default 'First Page' search, which identified any patent document with the search term ('naloxone') mentioned on its cover page, generating 522 matches. Had we conducted the more comprehensive 'Full Text' search ('naloxone' mentioned in any full-text patent document), PatentScope would have identified over 19 000 matches, which would have exceeded our capacity for manual screening. Compared with online literature databases such as PubMed or Embase, the functionality of the PatentScope interface is less advanced, in that users cannot export full search results to a citation manager. For every PatentScope entry, we thus had to download associated documents individually to assess eligibility for inclusion in our review. We considered supplementing our PatentScope search with additional query of all national and regional patent offices for which our PatentScope 'naloxone' search had yielded relevant entries (Canada, China, European Union, Germany, Great Britain, Israel, Russia, Singapore, South Africa and United States; see Online Supplement 2). However, we concluded that this was not feasible due to their different search and output formats that are not always compatible with PatentScope: for instance, the British online database Ipsum of the UK Intellectual Property office only permits search by application or publication number (i.e. not by keyword, e.g. 'naloxone') [30] , and the United States Patent and Trademark Office offers two separate search modes: one for patent applications (Patent Application Full-Text and Image Database, AppFT) and one for issued patents (Patent Full-Text and Image Database; PatFT) [31] , whereas PatentScope does not provide such distinction.
The third limitation concerns the quality of the data retrieved: we did not have access to raw data, and our analysis was reliant upon summary data provided by the patent applicants. Consequently, the comparability of the PK results was limited by different analytical methods and result formats used in the individual studies included in the patent applications (e.g. bioavailability reported as F vs. F IM ; central tendency expressed as mean vs. median). For instance, for no apparent reason, we were unable to replicate the F-values that Euro-Celtique cited in-text when we used the PK values listed in the data appendix. Similarly, we remain uncertain about the actual concentration of the AntiOp formulation (10 mg mL À1 Naloxone HCl or 10 mg mL À1 Naloxone HCl dihydrate), which could have affected calculation of dose-adjusted values in Table 1 . There was also variability in the sampling periods (8-36 h), which may have impacted AUC-dependent measures (e.g. F%, F IM %). In terms of reliability of the mean values reported in Table 1 , it also needs to be borne in mind that the cross-over studies (which comprised pilot and registration trials) differed substantially in sample sizes (7-35 subjects per treatment arm). ). Consequently, while clinical efficacy of concentrated IN sprays is likely, there is the risk of inducing acute opioid withdrawal in overdose victims [32] . A recent qualitative analysis of heroin/opioid overdose reversals found instances of apparent excessive naloxone dosing and consequent 'over-antagonism', sometimes triggering discharge and active further drug-seeking [33] . Hepatic impairment also increases naloxone bioavailability, particularly relevant when larger fractions of buccal/sublingual or IN naloxone are swallowed [25] , potentially causing severe distress and adverse events from naloxone overantagonism in dependent patients.
Meaning of the review: possible mechanisms and implications for clinicians or policy-makers
The poor IN bioavailability of non-concentrated naloxone using the mucosal atomiser device also raises important questions [15] [16] [17] . From a scientific perspective, how can such low absorbed doses be effective if they are indeed succeeding in reversing overdose? Also, the continued use of improvised (i.e. dilute) IN naloxone kits needs review.
Sublingual naloxone. In October 2015, INSYS Therapeutics announced that its sublingual naloxone spray (formulation unknown) had been granted fast-track review by the FDA. Considering the low bioavailability reported by the Euro-Celtique study, it seems unlikely that sublingual naloxone will be clinically useful.
Unanswered questions and future research
Unanswered questions around non-injectable naloxone remain. All PK data reported in the referenced patent applications were from healthy volunteers. It remains unclear how these findings relate to the heroin/opioid users where non-response rates (i.e. response judged by ambulance personnel to need supplementary injected dose) around 18-26% have been reported for IN naloxone [34, 35] .
Secondly, there are limitations in our current understanding of the PKs and pharmacodynamics of naloxone. While this review largely focuses on the bioavailability of non-injectable naloxone relative to parenteral injection, the absolute naloxone plasma concentration range required to reverse opioid overdose remains unknown. This needs sorting. Because naloxone is a competitive antagonist, the therapeutic dose will likely differ by route of administration alongside inter-individual variability. Moreover, the naloxone dose required to reverse the effects of a specific opioid agonist will depend on the opioid agonist dose and its pharmacological properties, particularly its potency, duration of action and receptor affinity [36] .
An ongoing Australian double-blinded randomised clinical trial at the Sydney Medically Supervised Injecting Centre (trial ID: ACTRN12611000852954) compares IN (0.8 mg mL The 2014 WHO guidelines note that a 0.4-0.8 mg parenteral naloxone dose is effective in most cases to reverse opioid overdose. However, given that the duration of naloxone is shorter than that of many opioids, repeat doses of naloxone may need to be given [37] . The WHO guidelines advise that initial naloxone doses above 0.8 mg increase the likelihood of significant withdrawal symptoms [8] . For any therapeutic drug, dose-related adverse effects (i.e. opioid withdrawal symptoms in the case of naloxone) often occur around C max [38] , suggesting that novel naloxone formulations with C max above that of a 0.8 mg parenteral naloxone injection may pose elevated risk of adverse effects. Future studies should systematically monitor and assess reports of naloxone-related adverse effects (from the medical or community setting) in relation to the naloxone dose and formulation used.
Thirdly, while the PK data from the patent applications indicated a negative relationship between volume and naloxone uptake, they did not allow us to determine a cut-off for IN spray volume (volume above which naloxone is lost to pre or post-nasal drip). Definition of the maximum volume will affect repeat administrations of IN naloxone spray. This too needs resolution.
Finally, we present a new analytical method of synthesis of public patent data from the WIPO PatentScope database. The limitations discussed earlier illustrate that this exploratory method will require optimisation and would benefit from enhanced functionality of the PatentScope interface, so that review of a greater volume of patent documents would become manageable. A 'Patent Crawler' software has been trialled as a search tool that combines analysis of medication and patent databases [39] . Future opensource editions of such software may potentially help academics, clinicians and members of the general public retrieve medication-related information across patent databases and the peer-reviewed medical literature. If such open-source software becomes available, we hope that our search protocol provided in Table S1 of the Online Appendix will allow researchers to replicate our exploratory analysis with added capture capability. When replicating our search in the future, researchers might also find it helpful to work together with patent experts who will be familiar with the functionality of patent databases and the legal language of (the often broad) patent claims.
In the future, such syntheses would also be more valuable if data were presented uniformly: this would require investigators of non-injectable naloxone formulations (including pharmaceutical companies) to publish their data even if findings are negative (see e.g. AllTrials.net) [40] .
Conclusions
Over the past 15 years, IN naloxone sprays have been tested in humans, but no product was licensed and commercially available until late 2015 [1] . With an ongoing epidemic of prescription-opioid overdose deaths alongside a more recent rapid rise in heroin deaths, an IN naloxone spray is finally available to prevent overdose deaths in opioid users-a target population vastly underserved for decades. This first licensed noninjectable naloxone marks a significant milestone towards wider naloxone access and more effective prevention of opioid overdose deaths. High-concentrate IN naloxone has good bioavailability although, thus far, formal product testing has only involved healthy volunteers. It remains possible that high-concentrate formulations may provoke naloxone over-antagonism in opioiddependent patients. Options for dose-titration and alternative routes (e.g. buccal) also need exploration. We call for proper publication of PK data on naloxone products: only then can there be properly informed consideration of different naloxone products by the clinical, policy and scientific communities.
property on a novel buccal naloxone formulation with which JS and RM are involved.
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